- Review Article
- Published:
Cancer immunoediting: from immunosurveillance to tumor escape
Nature Immunologyvolume 3, pages991–998 (2002)Cite this article
64kAccesses
73Altmetric
Abstract
The concept that the immune system can recognize and destroy nascent transformed cells was originally embodied in the cancer immunosurveillance hypothesis of Burnet and Thomas. This hypothesis was abandoned shortly afterwards because of the absence of strong experimental evidence supporting the concept. New data, however, clearly show the existence of cancer immunosurveillance and also indicate that it may function as a component of a more general process of cancer immunoediting. This process is responsible for both eliminating tumors and sculpting the immunogenic phenotypes of tumors that eventually form in immunocompetent hosts. In this review, we will summarize the historical and experimental basis of cancer immunoediting and discuss its dual roles in promoting host protection against cancer and facilitating tumor escape from immune destruction.
This is a preview of subscription content,access via your institution
Access options
Subscription info for Japanese customers
We have a dedicated website for our Japanese customers. Please go tonatureasia.com to subscribe to this journal.
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ehrlich, P. Ueber den jetzigen stand der Karzinomforschung.Ned. Tijdschr. Geneeskd.5, 273–290 (1909).
Silverstein, A.M.A History of Immunology (Academic, San Diego, CA, 1989).
Old, L.J. & Boyse, E.A. Immunology of experimental tumors.Annu. Rev. Med.15, 167–186 (1964).
Klein, G. Tumor antigens.Annu. Rev. Microbiol.20, 223–252 (1966).
Burnet, F.M. Cancer—a biological approach.Brit. Med. J.1, 841–847 (1957).
Thomas, L. inCellular and Humoral Aspects of the Hypersensitive States (ed. Lawrence, H. S.) 529–532 (Hoeber-Harper, New York, 1959).
Burnet, F.M. The concept of immunological surveillance.Prog. Exp. Tumor Res.13, 1–27 (1970).
Burnet, F.M. Immunological factors in the process of carcinogenesis.Br. Med. Bull.20, 154–158 (1964).
Kaplan, H.S. Role of immunologic disturbance in human oncogenesis: some facts and fancies.Br. J. Cancer25, 620–634 (1971).
Stutman, O. Immunodepression and malignancy.Adv. Cancer Res.22, 261–422 (1975).
Grant, G.A. & Miller, J.F. Effect of neonatal thymectomy on the induction of sarcomata in C57BL mice.Nature205, 1124–1125 (1965).
Nishizuka, Y., Nakakuki, K. & Usui, M. Enhancing effect of thymectomy on hepatotumorigenesis in Swiss mice following neonatal injection of 20-methylcholanthrene.Nature205, 1236–1238 (1965).
Trainin, N., Linker-Israeli, M., Small, M. & Boiato-Chen, L. Enhancement of lung adenoma formation by neonatal thymectomy in mice treated with 7,12-dimethylbenz(a)anthracene or urethan.Int. J. Cancer2, 326–336 (1967).
Burstein, N.A. & Law, L.W. Neonatal thymectomy and non-viral mammary tumours in mice.Nature231, 450–452 (1971).
Sanford, B.H., Kohn, H.I., Daly, J.J. & Soo, S.F. Long-term spontaneous tumor incidence in neonatally thymectomized mice.J. Immunol.110, 1437–1439 (1973).
Klein, G. Immunological surveillance against neoplasia.Harvey Lect., 71–102 (1973).
Flanagan, S.P. 'Nude', a new hairless gene with pleiotropic effects in the mouse.Genet. Res.8, 295–309 (1966).
Pantelouris, E.M. Absence of thymus in a mouse mutant.Nature217, 370–371 (1968).
Stutman, O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice.Science183, 534–536 (1974).
Stutman, O. inProceedings of the International Workshop on Nude Mice Vol.1 (eds. Rygaard, J. & Poulsen, C.) 257–264 (Gustav Fischer, Stuttgart 1973).
Stutman, O. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous and heterozygous matings and effect of age and carcinogen dose.J. Natl. Cancer Inst.2, 353–358 (1979).
Outzen, H.C., Custer, R.P., Eaton, G.J. & Prehn, R.T. Spontaneous and induced tumor incidence in germfree “nude” mice.J. Reticuloendothel. Soc.17, 1–9 (1975).
Stutman, O. inThe Nude Mouse in Experimental and Clinical Research (eds. Fogh, J. & Giovanella, B. C.) 411–435 (Academic, New York, 1978).
Rygaard, J. & Povlsen, C.O. Is immunological surveillance not a cell-mediated immune function?Transplantation17, 135–136 (1974).
Rygaard, J. & Povlsen, C.O. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance.Acta Pathol. Microbiol. Scand. [B] Microbiol. Immunol.82, 99–106 (1974).
Maleckar, J.R. & Sherman, L.A. The composition of the T cell receptor repertoire in nude mice.J. Immunol.138, 3873–3876 (1987).
Ikehara, S., Pahwa, R.N., Fernandes, G., Hansen, C.T. & Good, R.A. Functional T cells in athymic nude mice.Proc. Natl. Acad. Sci. USA81, 886–888 (1984).
Hunig, T. T-cell function and specificity in athymic mice.Immunol. Today4, 84–87 (1983).
Heidelberger, C. Chemical carcinogenesis.Annu. Rev. Biochem.44, 79–121 (1975).
Kouri, R.E. & Nebert, D.W. inOrigins of Human Cancer (eds. Hiatt, H. H., Watson, J. D. & Winsten, J. A.) 811–835 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1977).
Hayday, A.C. γδ cells: a right time and a right place for a conserved third way of protection.Annu. Rev. Immunol.18, 975–1026 (2000).
Prehn, R.T. Perspectives on oncogenesis: does immunity stimulate or inhibit neoplasia?J. Reticuloenothel. Soc.10, 1–16 (1970).
Thomas, L. On immunosurveillance in human cancer.Yale J. Biol. Med.55, 329–333 (1982).
Hanahan, D. & Weinberg, R.A. The hallmarks of cancer.Cell100, 57–70 (2000).
Herberman, R.B. & Holden, H.T. Natural cell-mediated immunity.Adv. Cancer Res.27, 305–377 (1978).
Engel, A.M. et al. Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression.APMIS104, 629–639 (1996).
Engel, A.M., Svane, I.M., Rygaard, J. & Werdelin, O. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice.Scand. J. Immunol.45, 463–470 (1997).
Schuler, W. et al. Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency.Cell46, 963–972 (1986).
Featherstone, C. & Jackson, S.P. DNA double-strand break repair.Curr. Biol.9, R759–R761 (1999).
Dighe, A.S., Richards, E., Old, L.J. & Schreiber, R.D. Enhancedin vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors.Immunity1, 447–456 (1994).
Kaplan, D.H. et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice.Proc. Natl. Acad. Sci. USA95, 7556–7561 (1998).
Street, S.E., Cretney, E. & Smyth, M.J. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis.Blood97, 192–197 (2001).
Street, S.E., Trapani, J.A., MacGregor, D. & Smyth, M.J. Suppression of lymphoma and epithelial malignancies effected by interferon γ.J. Exp. Med.196, 129–134 (2002).
Russell, J.H. & Ley, T.J. Lymphocyte-mediated cytotoxicity.Annu. Rev. Immunol.20, 323–370 (2002).
van den Broek, M.F. et al. Decreased tumor surveillance in perforin-deficient mice.J.Exp.Med.184, 1781–1790 (1996).
Smyth, M.J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells.J. Exp. Med.191, 661–668 (2000).
Smyth, M.J. et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma.J. Exp. Med.192, 755–760 (2000).
Shinkai, Y. et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement.Cell68, 855–867 (1992).
Shankaran, V. et al. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity.Nature410, 1107–1111 (2001).
Girardi, M. et al. Regulation of cutaneous malignancy by γδ T cells.Science294, 605–609 (2001).
Penn, I.Malignant Tumors in Organ Transplant Recipients (Springer-Verlag, New York, 1970).
Gatti, R.A. & Good, R.A. Occurrence of malignancy in immunodeficiency diseases. A literature review.Cancer28, 89–98 (1971).
Penn, I. Posttransplant malignancies.Transplant Proc.31, 1260–1262 (1999).
Birkeland, S.A. et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986.Int. J. Cancer60, 183–189 (1995).
Sheil, A.G.R. inKidney Transplantation (ed. Morris, P. J.) 558–570 (Saunders, Philadelphia, 2001).
Boshoff, C. & Weiss, R. AIDS-related malignancies.Nature Rev. Cancer2, 373–382 (2002).
Hoover, R.N. inOrigins of Human Cancer (eds. Hiatt, H. H., Watson, J. D. & Winsten, J. A.) 369–379 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1977).
Sheil, A.G. Cancer after transplantation.World J. Surg.10, 389–396 (1986).
Penn, I. Malignant melanoma in organ allograft recipients.Transplantation61, 274–278 (1996).
Penn, I. Sarcomas in organ allograft recipients.Transplantation60, 1485–1491 (1995).
Pham, S.M. et al. Solid tumors after heart transplantation: lethality of lung cancer.Ann. Thorac. Surg.60, 1623–1626 (1995).
Clark, W.H. Jr et al. Model predicting survival in stage I melanoma based on tumor progression.J. Natl. Cancer Inst.81, 1893–1904 (1989).
Clemente, C.G. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.Cancer77, 1303–1310 (1996).
Mihm, M.C. Jr, Clemente, C.G. & Cascinelli, N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.Lab. Invest.74, 43–47 (1996).
Rilke, F. et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors.Int. J. Cancer49, 44–49 (1991).
Lipponen, P.K., Eskelinen, M.J., Jauhiainen, K., Harju, E. & Terho, R. Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer.Eur. J. Cancer29A, 69–75 (1992).
Nacopoulou, L., Azaris, P., Papacharalampous, N. & Davaris, P. Prognostic significance of histologic host response in cancer of the large bowel.Cancer47, 930–936 (1981).
Naito, Y. et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.Cancer Res.58, 3491–3494 (1998).
Epstein, N.A. & Fatti, L.P. Prostatic carcinoma: some morphological features affecting prognosis.Cancer37, 2455–2465 (1976).
Deligdisch, L., Jacobs, A.J. & Cohen, C.J. Histologic correlates of virulence in ovarian adenocarcinoma. II. Morphologic correlates of host response.Am. J. Obstet. Gynecol.144, 885–889 (1982).
Jass, J.R. Lymphocytic infiltration and survival in rectal cancer.J. Clin. Pathol.39, 585–589 (1986).
Palma, L., Di Lorenzo, N. & Guidetti, B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases.J. Neurosurg.49, 854–861 (1978).
Uyttenhove, C., Van Snick, J. & Boon, T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.J. Exp. Med.152, 1175–1183 (1980).
Urban, J.L., Holland, J.M., Kripke, M.L. & Schreiber, H. Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation.J. Exp. Med.156, 1025–1041 (1982).
Svane, I.M. et al. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice.Eur. J. Immunol.26, 1844–1850 (1996).
Lengauer, C., Kinzler, K.W. & Vogelstein, B. Genetic instabilities in human cancers.Nature396, 643–649 (1998).
Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.Cell86, 353–364 (1996).
Smyth, M.J., Godfrey, D.I. & Trapani, J.A. A fresh look at tumor immunosurveillance and immunotherapy.Nature Immunol.2, 293–299 (2001).
Matzinger, P. Tolerance, danger, and the extended family.Annu. Rev. Immunol.12, 991–1045 (1994).
Yokoyama, W.M. Now you see it, now you don't!Nature Immunol.1, 95–97 (2000).
Cerwenka, A. et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice.Immunity12, 721–727 (2000).
Diefenbach, A., Jensen, E.R., Jamieson, A.M. & Raulet, D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.Nature413, 165–171 (2001).
Bromberg, J.F., Horvath, C.M., Wen, Z., Schreiber, R.D. & Darnell, J.E. Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon α and interferon γ.Proc. Natl. Acad. Sci. USA93, 7673–7678 (1996).
Kumar, A., Commane, M., Flickinger, T.W., Horvath, C.M. & Stark, G.R. Defective TNF-α-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases.Science278, 1630–1632 (1997).
Luster, A.D. & Ravetch, J.V. Biochemical characterization of a γ interferon-inducible cytokine (IP-10).J. Exp. Med.166, 1084–1097 (1987).
Liao, F. et al. Human Mig chemokine: biochemical and functional characterization.J. Exp. Med.182, 1301–1314 (1995).
Cole, K.E. et al. Interferon-inducible T cell α chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3.J. Exp. Med.187, 2009–2021 (1998).
Luster, A.D. & Leder, P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor responsein vivo.J. Exp. Med.178, 1057–1065 (1993).
Sgadari, C., Angiolillo, A.L. & Tosato, G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10.Blood87, 3877–3882 (1996).
Coughlin, C.M. et al. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis.Immunity9, 25–34 (1998).
Qin, Z. & Blankenstein, T. CD4+ T cell–mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells.Immunity12, 677–686 (2000).
Bancroft, G.J., Schreiber, R.D. & Unanue, E.R. Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse.Immunol. Rev.124, 5–24 (1991).
Trinchieri, G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.Annu. Rev. Immunol.13, 251–276 (1995).
Ikeda, H., Old, L.J. & Schreiber, R.D. The roles of IFN-γ in protection against tumor development and cancer immunoediting.Cytokine Growth Factor Rev.13, 95–109 (2002).
Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development.J. Exp. Med.195, 161–169 (2002).
Pardoll, D.M. Spinning molecular immunology into successful immunotherapy.Nature Rev. Immunol.2, 227–238 (2002).
Gerosa, F. et al. Reciprocal activating interaction between natural killer cells and dendritic cells.J. Exp. Med.195, 327–333 (2002).
Ferlazzo, G. et al. Human dendritic cells activate resting natural killer (NK) cells and are recognizedvia the NKp30 receptor by activated NK cells.J. Exp. Med.195, 343–351 (2002).
Piccioli, D., Sbrana, S., Melandri, E. & Valiante, N.M. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells.J. Exp. Med.195, 335–341 (2002).
Smyth, M.J., Crowe, N.Y. & Godfrey, D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.Int. Immunol.13, 459–463 (2001).
Noguchi, Y., Jungbluth, A., Richards, E. & Old, L.J. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene.Proc. Natl. Acad. Sci. USA93, 11798–11801 (1996).
Acknowledgements
Supported by grants from the National Cancer Institute (CA43059 and CA76464 to R. D. S.), the Cancer Research Institute (to R. D. S., H.I and A.B.), the Ludwig Institute for Cancer Research (to R. D. S.), and the National Institute of Allergy and Infectious Diseases (to R. D. S. and G. P. D.). We thank V. Shankaran, K. Sheehan, A. Dighe, D. Kaplan, R. Uppaluri, C. Koebel, J. Bui, E. Stockert, E. Richards, M. White, C. Arthur and C. Brendel for their important roles in developing the cancer immunoediting concept and for helpful comments during the preparation of this manuscript.
Author information
Authors and Affiliations
Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, 63110, MO, USA
Gavin P. Dunn, Allen T. Bruce, Hiroaki Ikeda & Robert D. Schreiber
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, 10021, NY, USA
Lloyd J. Old
- Gavin P. Dunn
You can also search for this author inPubMed Google Scholar
- Allen T. Bruce
You can also search for this author inPubMed Google Scholar
- Hiroaki Ikeda
You can also search for this author inPubMed Google Scholar
- Lloyd J. Old
You can also search for this author inPubMed Google Scholar
- Robert D. Schreiber
You can also search for this author inPubMed Google Scholar
Corresponding author
Correspondence toRobert D. Schreiber.
Rights and permissions
About this article
Cite this article
Dunn, G., Bruce, A., Ikeda, H.et al. Cancer immunoediting: from immunosurveillance to tumor escape.Nat Immunol3, 991–998 (2002). https://doi.org/10.1038/ni1102-991
Issue Date:
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
